UBS Group’s Asterias Biotherapeutics Warrants AST.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
– Sell
-3,870
Closed -$2K – 8430
2017
Q2
$2K Buy
3,870
+2,615
+208% +$1.18K ﹤0.01% 7466
2017
Q1
$0 Buy
1,255
+442
+54% +$162 ﹤0.01% 8474
2016
Q4
$0 Buy
813
+690
+561% +$369 ﹤0.01% 8496
2016
Q3
$0 Sell
123
-1,061
-90% -$290 ﹤0.01% 8398
2016
Q2
$0 Buy
+1,184
New +$617 ﹤0.01% 8420

UBS Group's AST.WS Position: Q3 2017 in Review

UBS Group sold out of Asterias Biotherapeutics Warrants (AST.WS) in Q3 2017, closing a stake of 3,870 shares — an estimated $2K sold.

UBS Group first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $2K in Q2 2017. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • UBS Group reported no remaining Asterias Biotherapeutics Warrants position as of Q3 2017 after selling out during the quarter.
  • UBS Group sold 3,870 Asterias Biotherapeutics Warrants shares in Q3 2017, an estimated $2K.
  • UBS Group first reported a position in Asterias Biotherapeutics Warrants in Q2 2016 and held it in 5 quarters.
  • UBS Group's Asterias Biotherapeutics Warrants position peaked at $2K in Q2 2017.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Warrants as of Q3 2017.

Based on UBS Group's 13F filing for Q3 2017, filed 14 Nov 2017.